ReviewFrontiers in microbiology2025
Unlocking the biotechnological potential of Baltic microorganisms.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Screening of 44 Baltic Sea Cyanobacterial Strains for Antibacterial and Quorum Sensing Inhibitory Potential: Selection of Promising Candidates.Antibiotics (Basel, Switzerland) · 2026Article
- Cytotoxic Activity of the Baltic CyanobacteriumToxins · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine microorganisms are increasingly recognized as valuable sources of bioactive compounds and enzymes with diverse applications in biotechnology. Despite its relatively low overall biodiversity, the Baltic Sea harbours a variety of diatoms, dinoflagellates, bacteria (including cyanobacteria), fungi, and bacteriophages with notable biotechnological potential. These organisms produce metabolites with promising application in environmental remediation or as components of pharmaceuticals, nutraceuticals, cosmetics and biomaterials. Enzymes produced by Baltic Sea bacteria catalyse reactions of industrial relevance, while bacteriophages may provide novel tools for pathogen control in aquaculture or serve as sources of genes encoding for valuable enzymes. Although advances in high-throughput genomics and metabolomics have accelerated marine biodiscovery, Baltic Sea microorganisms remain largely understudied and underexploited by industry. This review synthesizes current knowledge on the biotechnological potential of the Baltic Sea microorganisms and highlights opportunities to bridge the gap between basic research and commercial application, particularly in the context of international frameworks such as the Nagoya Protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.